Trial Profile

A Phase 1 Dose Escalation Study of EOC317 in Chinese Patients With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 04 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs EOC 317 (Primary)
Indications Advanced breast cancer; Bladder cancer; Cholangiocarcinoma; Gastric cancer; Male breast cancer; Solid tumours
Focus Adverse reactions
Sponsors EOC Pharma

Most Recent Events

10 Sep 2019 Planned primary completion date changed from 29 May 2019 to 29 Feb 2020.
19 Jul 2018 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com